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Summary DNA index and S-phase fraction (SPF) were measured by flow cytometry on paraffin embedded
tissue from 140 primary breast tumours. The results of DNA analysis were compared with the size, degree of
axillary node involvement, histological grade and steroid receptor content of the tumours, as well as with the
patients' subsequent clinical course. Forty-four (31.4%) of the 140 tumours were diploid. S-phase fraction was
evaluable for 134 (95.7%). The median SPF ofthe whole population was 7.1%, with diploid tumours having a significantly lower median SPF (3.2%) than aneuploid (10.1%, P<0.001). Both aneuploidy (P=0.002) and
high SPF (P<0.001) were strongly associated with high histological grade. There was no significant associa-
tion between either DNA ploidy or SPF and tumour size, nodal status or steroid receptor content. An SPF
below the median was strongly associated with better relapse-free survival (P=0.008), overall survival
(P=0.004) and survival after relapse (P<0.001). Ploidy did not correlate significantly with clinical course.
Multivariate analysis using the Cox model suggested that, while SPF gave prognostic information independent
of tumour size or nodal status, this independent significance was lost when histological grade was included in the analysis.
The number of axillary lymph nodes involved by tumour is
the single most important prognostic factor for women with
primary breast cancer (Fisher et al., 1968). Both oestrogen
and progesterone receptor levels also have predictive value,
patients with receptor negative tumours having a shorter
relapse-free survival and overall survival (Allegra et al., 1979;
Mason, 1983), this effect being most apparent after first
relapse (Stewart et al., 1981). However, these prognostic
factors alone do not fully account for the varied clinical
course seen in breast cancer patients. In recent years, the
proliferative rate of tumours has been widely investigated in
an attempt further to define prognostic subgroups. Flow
cytometry enables the automated measurement of both the
amount of cellular DNA and the percentage of cells in
different phases of the cell cycle. It can be performed on
paraffin embedded tissue, thus allowing a retrospective
evaluation of the relationship between these variables and
clinical outcome.
Many studies have shown correlations between cellular
DNA content, as measured by flow cytometry, and other
pretreatment factors (Moran et al., 1984; Kute et al., 1985;
Thorud et al., 1986; Dressler et al., 1988; Feichter et al.,
1988). Fewer have examined the relationship between the
results of flow-cytometric DNA analysis, in particular S-
phase fraction, and clinical course. In those studies which
have been reported the results are not clearcut. Patients
whose tumours have a low proportion of cells in S phase do
appear to have a better prognosis (Kallioniemi et al., 1986).
Recent reports also show a relapse-free survival and survival
advantage for patients with diploid tumours (Cornelisse et
al., 1987; Hedley et al., 1987; Kallioniemi et al., 1987),
although this finding is not universal (Klintenberg et al.,
1986), and may be confined to sugroups defined by other
prognostic factors (Cornelisse et al., 1987).
The aim of this study was to assess the relationship
between the results of DNA flow cytometry and clinical
outcome in patients followed up for a minimum of 8 years.
Material and methods
Patients
One hundred and sixty-nine patients with stage I (axillary
node negative) or stage II (axillary node positive) breast
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cancer had sections from the primary tumour sent for DNA
flow cytometry. These patients were randomly selected from
512 patients who presented to the ICRF Breast Unit at
Guy's Hospital between May 1973 and March 1980, giving a
minimum of 8 years follow-up for all patients, and included
both patients who had and patients who had not subse-
quently recurred. Modified radical mastectomy (total mastec-
tomy with axillary clearance) was the primary treatment in
all cases. Postoperative radiotherapy was given only to
patients with medial and central tumours, who received
3,000cGy to the internal mammary chain. Nineteen patients
with stage II disease received melphalan as adjuvant therapy.
Patient characteristics are listed in Table I.
DNAflow cytometry
Flow cytometry was performed on cell suspensions prepared
from formalin fixed paraffin embedded tissue from the
primary tumour as described previously (Masters et al., 1987). Briefly, 50gm sections were cut, dewaxed, rehydrated
through a series of alcohols into water and treated in a
5 mg ml-' solution of pepsin at 37°C for 30 min at pH 1.5.
After needling, filtration through 35 gm pore sized polyester
gauze and incubation with I jig ml-' DAPI (4'6-diamidino-2-
phenylindol-dihydrochloride, Boehringer) the samples were
analysed using a Becton Dickinson FACS Analyser powered
by a mercury arc lamp. At least 10,000 cells were scanned to
construct each histogram. A histogram was considered inter-
pretable if the coefficient of variation (c.v.) was less than or
equal to 8%, with a mean c.v. for interpretable histograms of
4.9% (3.5-8.0). The DNA index was calculated by measur-
ing the position of any aneuploid Gl peak relative to the
normal GI/GO peak, with a DNA index (DI) of 1.0 indicat-
ing the presence of only diploid cells. For DNA diploid
tumours, the proportion ofcells in S phase was calculated by
the method of Baisch et al. (1975). For aneuploid tumours
with a DNA index> 1.2 a modification of this method was
used to calculate the S-phase fraction of the aneuploid cells
alone (Camplejohn et al., 1989).
Histologicalgrade
The histological grade of infiltating ductal tumours was
assessed by the method of Bloom and Richardson (1957). All
assessments ofgrade were made by a single observer (RRM).
Tumours were classified as grade I (well differentiated), grade
2 (moderately differentiated) or grade 3 (poorly
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differentiated) using a system which takes into account
mitotic activity, nuclear pleomorphism and tubule formation.
Steroid receptor assays
Oestrogen and progesterone receptor analysis was performed
by the method of King et al. (1979). For both receptors a
level of at least 10fmol mg-' cytosol protein was taken as
positive.
Statistical analysis
Possible correlations between the results of DNA analysis
and tumour size, histological grade, steroid receptor content
and number of axillary lymph nodes involved were examined
using x2-analysis. The Mann-Whitney test was used to
measure differences between median S phase values.
Univariate analysis by the log rank test was used to assess
the influence of ploidy and SPF on relapse-free survival,
overall survival and survival after relapse, and a multivariate
analysis using the stepwise Cox regression model (Cox, 1972)
was performed. Relapse-free survival was measured from the
date of primary treatment to date of first relapse
(locoregional or metastatic) (Hayward et al., 1977) and sur-
vival from the date of primary treatment to death.
Results
Interpretable DNA histograms were obtained for 140/169
(83%) of the tumours analysed. The characteristics of the 29
tumours with uninterpretable histograms did not differ
significantly in any other respects from those of the other
140, and these tumours were excluded from the subsequent
analysis. Forty-four (31.4%) of the 140 tumours were diploid
and 96 (68.6%) aneuploid. The majority of aneuploid
tumours (87/96) were simple hyperdiploid (1.0<DI< 1.9).
S-phase fractions (SPF) were calculated for 134 tumours
(95.7%). The median SPF of all tumours was 7.1 ± 0.6%.
The median SPF of aneuploid tumours (10.1 ± 0.3) was
significantly higher than that of diploid tumours (3.2 ± 0.5)
(P<0.01).
DNA analysis and other presentationfeatures
Histological grade was documented for 123 infiltrating ductal
carcinomas (Table I). DNA ploidy was assessed on all
infiltrating ductal tumours and SPF on 117. There was a
highly significant relationship between histological grade and
both SPF (Table II, P<0.001) and ploidy (Table III,
P= 0.002). No significant association was found between
tumour size and either DNA ploidy (P= 0.88) or SPF
Table I Patient characteristics (n = 140)
Age
Axillary nodes
Tumour size
Histology
ER
PR
median (years)
range
negative
positive
<2.0 cm
2-5 cm
unknown
Infiltrating ductal
grade I
grade II
grade III
Infiltrating lobular
Other
< 10 fmol mg-'
> 10 fmol mg-'
unknown
< 10 fmol mg-'
> 10 fmol mg-'
unknown
53
36-75
60
80
44
90
6
14
67
42
8
9
35
65
40
22
32
86
TableII Histologicalgradeand SPFinpatientswithinfiltratingductal
carcinoma (n = 117)
Sphasefraction
Low High
Grade 1 10 4
Grade 2 41 25 P<0.001
Grade 3 3 34
Low SPF<7.1; high SPF >7.1
Table III Histological grade and DNA ploidy in patients with
infiltrating ductal carcinoma (n = 123)
Diploid Aneuploid
Grade 1 6 8
Grade 2 26 41 P= 0.002
Grade 3 2 40
(P = 0.89). Similarly, axillary nodal status did not correlate
with ploidy (P = 0.3) or SPF (P = 0.2).
Oestrogen receptor status (ER) was recorded for 100
tumours and progesterone receptor (PgR) for 54 (Table I).
No significant assocation was observed between steroid
receptor status and the results of flow cytometry (ER vs
ploidy, P = 0.4; PgR vs ploidy, P = 0.4; ER vs SPF,
P=0.13; PgR vs SPF, P=0.2).
DNA analysis and clinical course
There was no significant difference in relapse-free survival,
overall survival or survival after relapse between diploid and
aneuploid tumours (Figure 1). There was, however, a strong
correlation between low SPF and longer relapse-free survival
(Figure 2a), overall survival (Figure 2b) and survival after
relapse (Figure 2c).
Multivariate analysis
The stepwise Cox regression model was used to assess the
independent prognostic significance of the pretreatment
variables measured. SPF, axillary nodal status, tumour size
and histological grade were entered as factors in the analysis.
SPF continued to give independent prognostic information
for RFS, overall survival and survival after relapse following
the inclusion of nodal status and tumour size (Table IV).
However with the inclusion of histological grade as a
variable, the independent prognostic significance of SPF was
lost, suggesting that the effect of SPF is mainly explained by
its strong correlation with grade.
Discussion
The proportion of diploid tumours in our study (31.4%) is
comparable with that reported by other centres (Moran et
al., 1984; Kute et al., 1985; Thorud et al., 1986). The median
SPF (7.1) is also close to that reported by others (McDivitt et
al., 1985; Kallioniemi et al., 1986; Dressler et al., 1988).
There are problems associated with the calculation of SPF
for both diploid and aneuploid breast tumours. For diploid
tumours, contamination by lymphoid and other non-malig-
nant cells can lead to a falsely low result for SPF. For
aneuploid tumours, the histograms of the aneuploid and
diploid sub-populations overlap, making calculation of the
SPF less accurate. The median SPF of diploid tumours in
this study (3.2%), however, was significantly lower than that
of aneuploid tumours (10.1%). This is in agreement with the
results of thymidine labelling studies estimating SPF in both
diploid and aneuploid tumours (McDivitt et al., 1985), and
suggests that we are measuring the SPF of two different
populations of tumours, diploid and aneuploid.
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Figure 1 a, DNA ploidy and relapse-free survival. b, DNA
ploidy and overall survival. c, DNA ploidy and survival after
relapse.
Table IV Multivariate analysis: decreases in statistical significance of
SPF as additional prognostic factors are sequentially added to the Cox
model
RFS(P) OS(P) SAR(P) Additionalfactors
0.008 0.004 <0.001 None
0.006 0.008 0.006 Nodal status
0.01 0.01 0.03 Nodal status & tumour size
0.3 0.32 0.5 Nodal status, tumour size & tumour
grade
RFS, relapse-free survival; OS, survival; SAR, survival after relapse.
with histologically poorly differentiated tumours, as has been
reported in many studies (Moran et al., 1984; Thorud et al.,
1986; Feichter et al., 1988). The absence of correlation
between the results of flow-cytometric DNA analysis and
either tumour size or axillary lymph node involvement has
also been noted by others (Moran eta I., 1984; Kute et al.,
1985; Feichter et al., 1988), and suggests that DNA analysis
and tumour stage provide different and independent inform-
ation about tumour biology.
Most recent studies have reported a weak but consistent
association between high SPF, aneuploidy and negative
receptor status (Moran et al., 1984; Cornelisse et al., 1987;
Feichter et al., 1988), although this is not a universal finding
(McDivitt et al., 1986; Klintenberg et at., 1986). Unfor-
tunately, because our study group were specifically chosen so
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Figure 2 a, SPF and relapse-free survival. b, SPF and overall
survival. c, SPF and survival after relapse.
as to have a long follow-up period, steroid receptors has not
been measured on all tumours. While there was a trend for
diploid tumours and those with low SPF to be receptor
negative, this did not reach statistical significance.
Patients whose tumours had a low SPF showed
significantly longer relapse-free survival, overall survival and
survival after relapse than those with high SPF. This finding
is in agreement with the results of recent studies of SPF
measured by flow cytometry (Kallioniemi et al., 1986; Hedley
et al., 1987). While longer relapse-free survival and overall
survival were seen in our patients with diploid tumours, the
improvement did not reach statistical significance.
In order to examine the relative importance of DNA
analysis as a prognostic factor in breast cancer the indepen-
dent prognostic significance of these results must be assessed.
The pretreatment variable most strongly associated with both
ploidy and SPF in our patients was histological grade of the
tumour, which is itself a good predictor of clinical outcome,
patients with poorly differentiated tumours having a shorter
relapse-free and overall survival (Bloom & Richardson,
1957). Multivariate analysis using the Cox model suggested
that SPF did provide prognostic information independent of
primary tumour size and axillary nodal status. Tumour grade
and SPF gave similar prognostic information on univariate
analysis, with grade being a marginally better predictor of
outcome. As tumour grade and SPF were very strongly
correlated, however, the inclusion of tumour grade in the
multivariate analysis abolished the independent significance
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of SPF. Thus, DNA analysis did not seem to give inform-
ation additional to that already obtained by assessment of
histological grade. Flow cytometric DNA analysis, however,
has the advantage of being an objective process which is not
as observer dependent. Inter-observer variation in grading
breast cancer can be considerable, with one study showing
agreement in only 23 of 158 tumours graded independently
by six observers, five of whom had been simultaneously
trained at the same institution (Delides et al., 1982).
This study confirms recent reports in showing an improved
relapse-free and overall survival for patients with low SPF in
a group of patients with relatively long follow-up. The only
other prognostic factor found to be significantly associated
with the results of DNA analysis was histological grade.
While DNA analysis did not give information independent of
tumour grade, it is a less subjective measurement. We are at
present analysing the results of DNA analysis in a larger
group of patients to assess whether it gives independent
prognostic information within subgroups.
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